mRNA cancer vaccines are one of the more visible investigational directions in melanoma. Personalized vaccines such as V940/mRNA-4157 are designed from mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → found in a person's tumor and are being tested with pembrolizumab after surgery for high-risk melanoma. The goal is to lower the chance of recurrence, but this remains trial-stage treatment rather than standard care. Phase 3 trials are extending immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → combinations and cellular therapies. Fianlimab (anti-LAG-3) combined with cemiplimab (anti-PD-1) is being tested against pembrolizumab in untreated unresectable or metastatic melanoma. SUPRAME compares the engineered T-cell receptor therapy IMA203 against several investigator's choice options in previously treated cutaneous melanoma. A Phase 4 ctDNA-guided trial tests addition of ipilimumab to nivolumab and relatlimab based on circulating tumor DNA. Phase 3 work is also assessing intermittent versus continuous PD-1 therapy in metastatic disease. Earlier studies include TIL therapies engineered with membrane-bound IL-15, PRAME-targeted T-cell receptor NK cells, novel RNA lipid particle vaccines, oncolytic and bispecific approaches such as REGN10597 with cemiplimab, and the combination of fianlimab, cemiplimab, and ipilimumab. For mucosal melanoma, an underserved subtype, adjuvant short-course radiotherapy plus chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and a PD-1 inhibitor is being tested. Laboratory work has identified BET inhibitors as immunogenicity boosters, KLRG1 as a new checkpoint target, mechanisms of drug-tolerant persister cell formation, and immune signatures that predict non-response to PD-1 therapy.
Where the evidence stands
Single-agent and combination immune checkpoint blockade and BRAF and MEK inhibition are firmly established with overall survivalThe percentage of patients still alive after a set period — a key clinical trial endpoint.Click for full explanation → benefits and have changed long-term outcomes in advanced melanoma. TIL therapy with lifileucel is now an approved option for refractory disease, the first cellular therapy in a solid tumor. The next wave, anti-LAG-3 combinations, engineered T-cell receptor cell therapies, and radioligand or bispecific approaches, is in late Phase 3. Mucosal and uveal melanoma remain harder to treat, with targeted approaches in earlier development.
What this means for people affected
Cutaneous melanoma has seen one of the most dramatic survival improvements in oncology over the past 15 years, with long-term survival now possible in metastatic disease for many people receiving immune checkpoint blockade. BRAF mutationA change in DNA sequence that can drive cancer development.Click for full explanation → testing is standard at diagnosis of advanced disease and shapes targeted therapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → decisions. Resistance to immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → is the central remaining challenge, and several trials, including TIL therapies, anti-LAG-3 combinations, and engineered cell therapies, address this. Mucosal and uveal melanoma have fewer options and generally warrant clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → consideration. Adjuvant and neoadjuvant immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → approaches for resectable disease are also active areas of research.
Last updated May 22, 2026
Recent research findings
Understanding evidence levels▼
PreclínicoLab or cell studies — no human data yet.
Estudio en animalesResults in animals only — may not apply to humans.
Ensayo Fase 1First-in-human safety testing in small groups.
Ensayo Fase 2Early effectiveness testing in a larger group.
Ensayo Fase 3Large controlled trial — the strongest trial evidence.
Estudio observacionalPatterns observed in populations — not a controlled trial.
RevisiónSummary analysis of multiple existing studies.
MetaanálisisStatistical pooling of results from multiple studies.
Ensayo Fase 1/2Ensayo combinado de seguridad y eficacia inicial en humanos.Published: May 22, 2026
Pegenzileukin and Cemiplimab Combination Shows Promise in Treating Advanced Skin Cancers
Researchers tested a combination of two drugs, pegenzileukin and cemiplimab, in patients with advanced skin cancers. The study found that this combination was effective in some patients, with a high response rateThe proportion of patients whose cancer shrinks or disappears after treatment.Click for full explanation → and manageable side effects. However, more research is needed to confirm these findings.
Why it matters: This study provides new insights into the treatment of advanced skin cancers and may lead to improved treatment options for patients.
Efficacy
The objective response rate was 40% in Cohort A1 and 56.3% in Cohort B1.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 21, 2026
Genetic Factors May Influence Antibody Response to Cancer Treatment
Researchers studied how genetic factors affect the development of antibodies against a cancer treatment called nivolumab when used in combination with another treatment. They found that certain genetic variations may increase the risk of developing these antibodies. More research is needed to understand the implications of these findings.
Why it matters: This study may help identify patients who are at higher risk of developing antibodies against nivolumab, which could inform treatment decisions in the future.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 21, 2026
Evaluating AI Models for Cancer Treatment Information
Researchers tested how well artificial intelligence models can identify cancer treatment information from text. They found that these models perform better when given the right instructions and struggle with complex tasks. The results suggest that AI models should be used with caution and carefully evaluated.
Why it matters: This finding is important for understanding how AI can be used to support cancer treatment research and decision-making.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 21, 2026
Macrophages in Skin Help Contain Melanoma Growth
Researchers studied how macrophages in the skin interact with melanoma cells. They found that a specific type of macrophage, CD169+, can engulf and ingest live tumor cells, which helps to slow down melanoma growth. However, when these macrophages are depleted, the tumors grow faster.
Why it matters: This finding could lead to new ways to target melanoma cells and improve treatment outcomes.
This study was conducted in a syngeneic melanoma model, which is a type of animal study.
⚡ Hallazgo mayorEvidencia en una etapa avanzada con una eficacia especialmente fuerte, por lo general de un ensayo de fase 3 o un metaanálisis.Ensayo Fase 3Ensayo controlado de gran escala que compara tratamientos. El nivel más sólido de evidencia de ensayo.Published: May 20, 2026
New Cancer Treatment Shows Promise for Uveal Melanoma Patients
Researchers developed a new treatment called tebentafusp, which targets a specific type of cancer called uveal melanoma. In a clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation →, patients who received tebentafusp lived longer than those who received standard treatment. The treatment works by activating the immune system to attack cancer cells.
Why it matters: This finding could lead to new treatment options for patients with uveal melanoma.
Efficacy
Tebentafusp significantly improved overall-survival versus investigator's choice.
Estudio observacionalPatrones observados en poblaciones a lo largo del tiempo, no es un experimento controlado.Published: May 19, 2026
Rare Side Effect of Cancer Treatment: Lymphocytic Colitis
Researchers reported a case of a man with metastatic melanoma who developed a rare side effect, lymphocytic colitis, while taking a combination of cancer treatments. The symptoms persisted even after stopping one of the treatments. A flexible sigmoidoscopy and biopsy confirmed the diagnosis.
Why it matters: This case highlights the challenges of diagnosing side effects of cancer treatments and the importance of further research to understand these complications.
Estudio observacionalPatrones observados en poblaciones a lo largo del tiempo, no es un experimento controlado.Published: May 19, 2026
Tailored treatment for melanoma patient with bleeding brain metastases and blood clots
Researchers treated a 62-year-old man with advanced melanoma who had bleeding brain metastases and blood clots in his leg. They used a combination of treatments, including immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →, radiotherapy, and targeted therapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation →, and also performed a procedure to remove the blood clot. The patient experienced some benefits from the treatment, but also had some setbacks.
Why it matters: This case highlights the importance of a personalized approach to treating patients with complex and aggressive forms of cancer.
A single case study, which may not be representative of all patients with similar conditions.
PreclínicoEstudios de laboratorio o celulares. Sin datos humanos aún.Est. completion: February 2, 2027
Testing an Educational Tool for Melanoma Patients with Autoimmune Disease
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying an educational tool for patients with melanoma who also have an autoimmune disease and are considering treatment with immune checkpoint inhibitors. The trial aims to understand the effectiveness of this tool in helping patients make informed decisions. The trial is currently recruiting participants.
Why it matters: This trial matters because it may help improve the experience of patients with melanoma and autoimmune disease by providing them with better information and support.
Ensayo Fase 1Primer ensayo en humanos. Se centra en la seguridad y dosificación en grupos pequeños.Est. completion: November 30, 2027
Testing Aerosol Gemcitabine for Solid Tumors with Lung Metastases
Researchers are studying the safety and effectiveness of aerosol gemcitabine in patients with solid tumors that have spread to the lungs. This trial is currently recruiting participants. The results of this study are not yet available.
Why it matters: This trial may help doctors understand how to treat patients with solid tumors that have spread to the lungs.
Ensayo Fase 1Primer ensayo en humanos. Se centra en la seguridad y dosificación en grupos pequeños.Est. completion: February 2, 2027
Antibiotic Use Before Surgery in Melanoma Patients
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the effect of taking an antibiotic called Cefazolin before surgery on the microbiome in patients with early-stage melanoma. The trial is currently active but not recruiting participants. The goal is to learn more about how this antibiotic affects the body's natural bacteria.
Why it matters: Understanding the impact of antibiotics on the microbiome in melanoma patients may help improve surgical outcomes and patient care.
Ensayo Fase 2Evalúa la eficacia inicial en un grupo más amplio después de establecer la seguridad en la fase 1.Est. completion: January 1, 2028
Testing a Combination Treatment for Metastatic Melanoma
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a combination of treatments for people with metastatic melanoma, a type of skin cancer. The treatments being tested are cryoablation, ipilimumab, and nivolumab. The trial is currently recruiting participants.
Why it matters: This trial aims to determine if the combination of these treatments can be an effective option for people with metastatic melanoma.
Ensayo Fase 2Evalúa la eficacia inicial en un grupo más amplio después de establecer la seguridad en la fase 1.Est. completion: February 1, 2030
Testing Combination Therapy for Melanoma Brain Metastases
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a combination of medications (relatlimab, nivolumab, and ipilimumab) for patients with melanoma that has spread to the brain. The trial is currently recruiting participants. The goal is to see how well this treatment works for people with this condition.
Why it matters: This trial may help doctors find a more effective treatment for patients with melanoma that has spread to the brain.
B7-H3-Specific Chimeric Antigen ReceptorA type of immunotherapy that genetically engineers a patient's own T cells to recognise and destroy cancer cells.Click for full explanation → Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
